PubRank

Lutz Gissmann

Author PubWeight™ 63.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Chapter 1: HPV in the etiology of human cancer. Vaccine 2006 6.61
2 Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006 3.13
3 Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 2009 1.92
4 E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog 2011 1.89
5 TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007 1.70
6 Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 2004 1.53
7 Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 2007 1.50
8 Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol 2004 1.32
9 Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep 2006 1.24
10 Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol 2014 1.23
11 Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 2004 1.13
12 Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 2008 1.12
13 Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003 1.12
14 Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer 2012 1.10
15 Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One 2012 1.08
16 Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 2008 1.07
17 Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 2003 1.07
18 Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol 2006 1.06
19 Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin. Vaccine 2009 1.05
20 Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer Res 2009 1.05
21 Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007 1.04
22 Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J Virol 2005 0.99
23 Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther 2012 0.98
24 Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. J Virol 2011 0.92
25 An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006 0.90
26 Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 2002 0.90
27 Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine 2009 0.89
28 IkappaB kinase beta promotes cell survival by antagonizing p53 functions through DeltaNp73alpha phosphorylation and stabilization. Mol Cell Biol 2011 0.89
29 Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol 2009 0.89
30 Enhanced papillomavirus-like particle production in insect cells. Virology 2009 0.87
31 Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly. Vaccine 2005 0.87
32 Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses. J Virol 2009 0.87
33 Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine 2009 0.87
34 Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. Int J Cancer 2009 0.86
35 Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors. Antivir Ther 2009 0.84
36 Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. Immunobiology 2007 0.84
37 T cell response to human papillomavirus 16 E7 in mice: comparison of Cr release assay, intracellular IFN-gamma production, ELISPOT and tetramer staining. Intervirology 2002 0.84
38 Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. Immunol Lett 2006 0.83
39 Prophylactic DNA immunization against multiple papillomavirus types. Vaccine 2007 0.83
40 NF-κ B-dependent upregulation of ICAM-1 by HPV16-E6/E7 facilitates NK cell/target cell interaction. Int J Cancer 2011 0.83
41 Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. Vaccine 2005 0.83
42 Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antivir Ther 2004 0.83
43 Human papillomavirus type 38 E6 and E7 act as tumour promoters during chemically induced skin carcinogenesis. J Gen Virol 2012 0.83
44 Tumor prevention in HPV8 transgenic mice by HPV8-E6 DNA vaccination. Med Microbiol Immunol 2014 0.83
45 The worldwide perspective on human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev 2012 0.82
46 Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine 2005 0.82
47 The HPV16 transcriptome in cervical lesions of different grades. Mol Cell Probes 2011 0.81
48 Expression of the HPV11 E2 gene in transgenic mice does not result in alterations of the phenotypic pattern. Transgenic Res 2007 0.81
49 Human papillomavirus-specific immune therapy: failure and hope. Antivir Ther 2010 0.79
50 Potato virus X coat protein fusion to human papillomavirus 16 E7 oncoprotein enhance antigen stability and accumulation in tobacco chloroplast. Mol Biotechnol 2009 0.79
51 New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antivir Ther 2011 0.79
52 HPV18 E6 and E7 genes affect cell cycle, pRB and p53 of cervical tumor cells and represent prominent candidates for intervention by use peptide nucleic acids (PNAs). Cancer Lett 2004 0.79
53 Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7. Antivir Ther 2008 0.78
54 Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles. J Gen Virol 2008 0.78
55 Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int J Cancer 2006 0.78
56 A long way: history of the prophylactic papillomavirus vaccine. Dis Markers 2007 0.77
57 Correction: E6 and E7 from Beta Hpv38 Cooperate with Ultraviolet Light in the Development of Actinic Keratosis-Like Lesions and Squamous Cell Carcinoma in Mice. PLoS Pathog 2016 0.75